Increased plasma conc w/ CYP3A4 inhibitors eg, troleandomycin, INH, grapefruit juice, PIs eg, indinavir, ritonavir. Decreased plasma conc w/ CYP3A4 inducers eg, rifampin, phenobarb, phenytoin. Increased/decreased plasma conc w/ CYP3A4 inihibitors (eg, aprepitant, fosaprepitant, itraconazole, ketoconazole, diltiazem, OCs, clarithromycin, erythromycin), inducers (eg, carbamazepine), substrates (eg, cyclosphosphamide, tacrolimus). Convulsions w/ ciclosporin. Enhanced/diminished effects of oral anticoagulants. Increased incidence of GI bleeding & ulceration w/ NSAIDs. Increased clearance of high-dose aspirin. Acute myopathy w/ high-dose anticholinergics eg, neuromuscular-blocking drugs. Antagonised neuromuscular-blocking effects of pancuronium & vecuronium. Increased blood glucose conc w/ antidiabetics. Hypokalemia w/ K-depleting agents eg, diuretics, amphotericin B, β2
-agonists, xanthenes; cardiac glycosides. Antagonized effects of diuretics, antihypertensives. Reduced effects by mifepristone. Incompatibility w/ allopurinol Na, doxapram HCl, tigecycline, Ca gluconate, rocuronium Br, cisatracurium besylate, glycopyrrolate, propofol.